Publication:
Challenges and achievements of liquid biopsy technologies employed in early breast cancer

Simple item page
dc.contributor.authorAlba-Bernal, Alfonso
dc.contributor.authorLavado-Valenzuela, Rocío
dc.contributor.authorDomínguez-Recio, María Emilia
dc.contributor.authorJiménez-Rodriguez, Begoña
dc.contributor.authorQueipo-Ortuño, María Isabel
dc.contributor.authorAlba, Emilio
dc.contributor.authorComino-Méndez, Iñaki
dc.contributor.authoraffiliation[Alba-Bernal,A; Lavado-Valenzuela,R; Domínguez-Recio,ME; Jiménez-Rodriguez,B; Queipo-Ortuño,MI; Alba,E; Comino-Méndez,I] Unidad de Gestion Clínica Intercentros de Oncología Medica, Hospitales Universitarios Regional y Virgen de la Victoria. The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), Málaga, Spain.
dc.date.accessioned2024-02-12T19:47:51Z
dc.date.available2024-02-12T19:47:51Z
dc.date.issued2020-11-09
dc.description.abstractBreast cancer is the most common cancer type in women worldwide and its early detection is crucial to curing the disease. Tissue biopsy, currently the method of choice to obtain tumour molecular information, is invasive and might be affected by tumour heterogeneity rendering it incapable to portray the complete molecular picture. Liquid biopsy permits to study disease features in a more comprehensive manner by sampling biofluids and extracting tumour components such as circulating-tumour DNA (ctDNA), circulating-tumour cells (CTCs), and/or circulating-tumour RNA (ctRNA) amongst others in a monitoring-compatible manner. In this review, we describe the recent progress in the utilization of the circulating tumour components using early breast cancer samples. We review the most important analytes and technologies employed for their study.
dc.description.sponsorshipICM's contract is funded by the Spanish Association Against Cancer (AECC). AAB is contracted by the “Garantía Juvenil en I+D+i Subprograma Estatal de Incorporacion” by the Ministry of Science and Innovation (Spanish Government). MIQO contract is supported by the “Miguel Servet Type II” program (CPI13/00003), ISCIII, Spain and cofunded by the "Fondo Europeo de Desarrollo Regional-(FEDER)", and by the “Nicolas Monardes” research program from the "Consejería de Salud" (C-0030-2018), Andalusian Gobernment, Spain.
dc.identifier.doi10.1016/j.ebiom.2020.103100
dc.identifier.e-issn2352-3964es_ES
dc.identifier.journalEBioMedicinees_ES
dc.identifier.otherhttp://hdl.handle.net/10668/3766
dc.identifier.pubmedID33161226es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18149
dc.language.isoeng
dc.publisherElsevier
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S235239642030476X?via%3Dihubes
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectLiquid biopsy
dc.subjectLocalized breast cancer
dc.subjectCirculating-tumour DNA
dc.subjectCirculating-tumour cells
dc.subjectCirculating-tumour RNA
dc.subjectBiopsia líquida
dc.subjectNeoplasias de la mama
dc.subjectARN
dc.subjectADN
dc.subjectCélulas
dc.subjectARN Circular
dc.subjectPacientes
dc.subject.meshBreast Neoplasms
dc.subject.meshDNA, Neoplasm
dc.subject.meshDisease Management
dc.subject.meshDisease Susceptibility
dc.subject.meshEarly Detection of Cancer
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshBiopsy
dc.subject.meshNeoplastic Cells, Circulating
dc.subject.meshMicroRNAs
dc.subject.meshPatients
dc.titleChallenges and achievements of liquid biopsy technologies employed in early breast cancer
dc.typereview article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Collections

IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)